Abstracts

SLEEP AND FRAILTY AMONG MEN WITH AND WITHOUT HIV

Persons with HIV (PWH) experience earlier onset and increased rates of frailty compared to those without HIV. Poor sleep quality has been associated with frailty in the general population. However, data are needed assessing associations between objective measures of sleep quality and frailty among PWH. The Multicenter AIDS Cohort Study (MACS) is a prospective study…

NETWORK ANALYSIS HIGHLIGHTS DIFFERENTIAL CLINICAL AND OMICS PROFILES IN HIV INFECTION

Some people living with HIV under long-term successful antiretroviral therapy (PLWH) suffer from cardiometabolic comorbidities, among other aging-related disorders. Though case-control studies comparing PLWH and HIV-negative control (HC) have been done previously, the heterogeneity among PLWH related to the incidence of metabolic diseases has not been investigated. To predict metabolic changes in PLWH, we aim to…

POST-ACUTE SEQUELAE OF SARS-CoV-2 IN NONHOSPITALIZED ACTIV-2 TRIAL PARTICIPANTS

Randomized COVID-19 trials provide opportunities to describe post-acute sequelae of SARS-CoV-2 (PASC)-related symptom burden longitudinally and assess the impact of early use of antivirals on PASC prevalence. ACTIV-2 evaluates safety and efficacy of investigational agents for non-hospitalized adults with mild to moderate COVID-19 in a Phase 2/3 trial. In Phase 2, participants were randomized within…

CLINICAL CONDITIONS ASSOCIATED WITH PASC IN KAISER PERMANENTE MID-ATLANTIC STATES

The natural history of the longer-term effects of SARS-CoV-2 (COVID-19), known as Post-Acute Sequelae of SARS-CoV-2 (PASC), is limited. Disease characterization and definition changed over time and identification via standard diagnosis codes was only recently enacted. We aim to identify a cohort of individuals with, or at-risk for, PASC among Kaiser Permanente Mid-Atlantic States (KPMAS)…

PERSISTENT COVID-19 SYMPTOMS ARE HIGHLY PREVALENT 12 MONTHS AFTER HOSPITALIZATION

Persistent COVID-19 symptoms have been reported up to six months (M6) after hospital discharge. Little is known on the frequency and the nature of persistent symptoms beyond M6. Here we assessed, in the longitudinal prospective French COVID-19 cohort, symptoms that persisted twelve months after admission for COVID-19. Hospitalized patients with a virologically-confirmed COVID-19 were enrolled.…